BeatO

Sector: Pharma & Healthcare (Fitness Wearables & Continuous Glucose Monitoring (CGM) Plant)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

BeatO operates in the pharma & healthcare segment of the Indian market, with a presence noted in the fitness wearables & continuous glucose monitoring (cgm) plant category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where BeatO is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in fitness wearables & continuous glucose monitoring (cgm) plant includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

March 2026

BeatO has advanced its position in India's diabetes care market through strategic partnerships and sustained capital raises. In mid-2024, the company joined forces with Policy Ensure to broaden diabetes awareness and improve insurance access for patients across India [3][4]. This collaboration supports BeatO's broader mission of making diabetes management more accessible, complementing its existing platform of connected glucometers and coaching services.

On the product front, BeatO received a favourable review for its 15-day CGM glucose monitoring system in March 2026, highlighting its smart continuous monitoring capabilities for diabetes management [2]. Financially, BeatO closed a $33 million Series B funding round led by Lightrock India in November 2022 [6][7], with the company subsequently confirming an additional $33 million raise from the same investor in August 2023 [5]. These capital raises provide runway for continued product development and market expansion in the competitive Indian CGM and digital diabetes care segment.

Sources (6)

1. BeatO CGM Glucose Monitor Review: Smart 15-Day Continuous Blood Sugar Monitoring System for Diabetes Management - gogi.in · gogi.in · Sat, 14 Mar 2026
2. Policy Ensure Partners with BeatO to Spread Diabetes Awareness and Insurance Access in India - The Times of India · The Times of India · Wed, 10 Jul 2024
3. BeatO and Policy Ensure Join Forces to Transform Diabetes Care in India - Business Standard · Business Standard · Fri, 05 Jul 2024
4. Diabetes care platform BeatO raises 33 mn led by Lightrock India - IMDb · IMDb · Wed, 30 Aug 2023
5. BeatO closes $33 Mn in funding led by Lightrock India - expresshealthcare.in · expresshealthcare.in · Wed, 16 Nov 2022
6. BeatO closes $33 Mn Series B round led by Lightrock India - Entrackr · Entrackr · Wed, 16 Nov 2022

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

BeatO occupies a position in the fitness wearables & continuous glucose monitoring (cgm) plant category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on fitness wearables & continuous glucose monitoring (cgm) plant benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the fitness wearables & continuous glucose monitoring (cgm) plant value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

BeatO is a participant in the Indian fitness wearables & continuous glucose monitoring (cgm) plant category, which forms part of the broader Pharma & Healthcare space. The Indian fitness wearables & continuous glucose monitoring (cgm) plant market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For BeatO specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for BeatO mirrors the broader fitness wearables & continuous glucose monitoring (cgm) plant category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for BeatO as a peer benchmark within the fitness wearables & continuous glucose monitoring (cgm) plant category. For investors, lenders, or new entrant promoters seeking a fuller assessment of BeatO, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with BeatO?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (fitness wearables & continuous glucose monitoring (cgm) plant) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of BeatO and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use BeatO in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.